›› 2018, Vol. 38 ›› Issue (5): 505-.doi: 10.3969/j.issn.1674-8115.2018.05.004

• Original article (Clinical research) • Previous Articles     Next Articles

Progression of left ventricular hypertrophy in maintenance hemodialysis patients and analysis of risk factors

CHEN Xiao-mei1, CHEN Zi-jin2, MA Xiao-bo2, ZHANG Chun-li2, QIAN Ying2, YU Hai-jin2, CHEN Xiao-nong2   

  1. 1. Nephrology Division, the First Hospital Affiliated to Wannan Medical College, Wuhu 241001, China; 2. Department of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
  • Online:2018-05-28 Published:2018-05-28
  • Supported by:
    National Natural Science Foundation of China, 81600590; Special Fund for Scientific Research of Public Welfare Industry of National Health and Family Planning Commission, OUMP2014-002; Project of National Science and Technology Supporting Plan, 2015BA112B05; Foundation of Shanghai Municipal Commission of Health and Family Planning, 20154Y0015; Project of Science and Technology Commission of Shanghai Municipality, 15441903505, 16DZ1930502

Abstract: Objective · To observe the progression of left ventricular hypertrophy (LVH) in maintenance hemodialysis (MHD) patients, and to analyse risk factors of the progression of LVH. Methods · SMHD patients of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine were enrolled in July 2012. These patients were followed for 1 year. Clinical characteristics and laboratory indices were collected at baseline and 1-year follow-up. Left ventricular mass (LVM) was evaluatedultrasonic cardiogram. Left ventricular mass index (LVMI) increased more than 5% was defined as LVH progression. Results · Totally 71 MHD patients were enrolled in this study. 44 patients were males, with median age 55.9 years old, median dialysis vintage 152.1 months. 22 (30.99%) patients had LVH at enrollment. A significant higher percentage of MHD patients used calcium-channel binder (CCB) and angiotensin-converting-enzyme inhibitor (ACEI) in LVH group, while a significant higher NT-proBNP level was also showed in LVH group. 31 patients had LVH progression while 40 patients didn’t after 1 year. Patients in progression group had significant higher levels of total cholesterol and low-density lipoprotein cholesterol (LDL-C). In univariable and multivariable Logistic regression, total cholesterol and LDL-C were independent risk factors of LVH progression (OR2.515, 95% CI 1.219-5.910, P0.013; OR1.950, 95% CI 1.127-3.375, P0.017). Conclusion · LVH is one of the common cardiovascular complications in MHD patients. The proportion of of antihypertensive drugs is higher in the patients with LVH. Higher LDL-C and total cholesterol levels are risk factors for the progression of LVH.

Key words: left ventricular hypertrophy, maintenance hemodialysis, low-density lipoprotein, cholesterol

CLC Number: